Is larotrectinib (Vitaca) an oral medicine or an injection medicine and how to use it?

Larotrectinib is a highly selective TRK (NTRK gene fusion) inhibitor, mainly used to treat patients with solid tumors with NTRK gene fusion. The drug was designed with the patient's convenience in mind and is therefore available as an oral formulation rather than an injection. The advantage of oral medicine is that it is simple to administer and can be used for a long time in an outpatient or home environment, which reduces the patient's burden of frequent trips to the hospital for infusions and improves the quality of life.

In terms of usage, larotrectinib is usually available in two dosage forms: capsules or oral solutions, suitable for patients of different ages and swallowing abilities. Adults and children who can swallow capsules mostly use capsule form, while oral solutions are recommended for infants and children or patients who cannot swallow solid preparations. The doctor will determine the dosage based on the patient's weight, age and specific condition to ensure that the drug has the best effect in the body.

Patients should follow medical advice when taking larotrectinib, usually twice a day, and try to take it at a fixed time to maintain the stability of the drug concentration in the body. This drug can be taken with food or on an empty stomach, but it is recommended to avoid combining it with strong CYP3A4 inhibitors or inducers to avoid affecting the efficacy of the drug or increasing the risk of adverse reactions. During the treatment process, if the patient misses a dose, he or she should take it as soon as possible. However, if the next dose is close, it is not recommended to double the dose.

In addition, patients need to undergo regular imaging and laboratory testing while taking larotrectinib to assess tumor response and monitor possible side effects. Common adverse reactions include fatigue, nausea, dizziness and abnormal liver function indicators. Most are mild to moderate and can be improved through dose adjustment or symptomatic treatment. Overall, as an oral targeted drug, larotrectinib is relatively easy to use and provides personalized and efficient treatment options for patients with NTRK fusion-positive tumors.

Reference link:https://www.drugs.com